<DOC>
	<DOCNO>NCT01673659</DOCNO>
	<brief_summary>The objective study demonstrate bioequivalence ( comparable safety efficacy ) Test product Reference treatment subject seasonal allergic rhinitis .</brief_summary>
	<brief_title>A Safety Bioequivalence Mometasone Nasal Spray , 50 Mcg/Actuation Compared With Nasonex® Nasal Spray 50 Mcg/Actuation Relief Symptoms Seasonal Allergic Rhinitis ( SAR )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>1 . Complete inform consent/assent process . 2 . Male female 1265 year age . 3 . Female subject childbearing potential must pregnant nursing , must negative urine pregnancy test abstain sexual intercourse use reliable method contraception study . 4 . Subjects eligible participate : ) Their total rTNSS least 6 ; b ) Reflective rating `` nasal congestion/stuffy nose '' score &gt; 2 Visit 1 ; c ) Reflective score &gt; 2 least one ( 1 ) remain three ( 3 ) allergic rhinitis symptom . 5 . A history ( 2 season ) seasonal allergy least one allergen know present study season , confirm skin prick test . ( A document positive skin test within previous 12 month acceptable . ) 1 . Female pregnant nursing , use agree use acceptable form contraception study , intend become pregnant study . 2 . Subject history hypersensitivity allergy Mometasone , corticosteroid study medication ingredient . 3 . Patients suffer chronic sign symptom Perennial Allergic Rhinitis ( PAR ) exclude study , unless Investigator assess patient 's current sign symptom clear exacerbation Seasonal Allergic Rhinitis ( SAR ) , rather chronic PAR . 4 . A total score le 6 rTNSS score less 2 `` nasal congestion '' score less 2 remain 3 symptom . 5 . Subject condition abnormality upper airway ( ex : nasal polyp , obstruction , recent nasal surgery , structural abnormality , rhinitis medicamentosa , etc . ) , opinion Investigator , could interfere administration product , evaluation subject 's condition , aspect trial . 6 . Subject experienced upper respiratory tract infection experience sinus infection within 30 day , history recurrent sinus infection i.e . acute significant chronic sinusitis , precede Visit 1 . 7 . Subject history asthma require chronic treatment within two year study start . 8 . Subject lack history seasonal allergy least one allergen know present study season least two precede season . 9 . Subject negative skin test appropriate allergen know present study season . 10 . Treatment oral Candidiasis within 30 day start study , current oral Candidiasis infection . 11 . The subject recent exposure ( 30 day ) risk expose chicken pox measles . 12 . Patients untreated fungal , bacterial , systemic viral infection within previous 30 day . 13 . Subject require treatment systemic corticosteroid condition , receive systemic nasal steroid within 30 day precede Visit 1 . Hormone replacement therapy allow , condition subject stable dose regimen least 90 day remain dose regimen study . 14 . Subject use systemic antiinflammatory agents* include aspirin** nonsteroidal antiinflammatory ( NSAIDs ) within 3 day prior Visit 1 . ( *Subjects may use Acetaminophen pain relief , need , throughout study . **Use lowdose aspirin cardiac prophylaxis allow ) . 15 . Subject immunotherapy ( include desensitization therapy perennial allergen seasonal allergen find current season ) initiate subject 's dosage frequency immunotherapy adjust within 30 day precede Visit 1 . 16 . Subject desensitization therapy seasonal allergen cause allergic rhinitis within previous 6 month . 17 . Subject present conjunctivitis eye signs/symptoms related diagnosis SAR . 18 . Subject use topical ( &gt; 1 % ) ophthalmic steroid preparation within 14 day precede Visit 1 . ( Topical steroid preparation use dermatological indication permit concentration ≤1 % . ) 19 . Use intranasal systemic first generation antihistamine , leukotriene receptor antagonist ( montelukast ) nasal decongestant within 3 day Visit 1 . 20 . Use intranasal cromolyn within 14 day Visit 1 . 21 . Use intranasal systemic secondgeneration antihistamine ( e.g . fexofenadine , loratadine , desloratadine , cetirizine ) within 10 day Visit 1 . 22 . Subject receive immunesystem therapy AIC ( investigational vaccine create use immunostimulatory sequence derive DNA ) , SLIT , Oral peptide sequence time . 23 . Subject clinically significant acute chronic hepatic disease . 24 . Subject history alcoholism , drug abuse , problem would likely make him/her unreliable study . 25 . Subject condition use medication , opinion Investigator , might interfere conduct result study place prospective subject increase risk . 26 . Subject receive tricyclic antidepressant within 30 day precede Visit 1 . 27 . Subject treat attentiondeficit hyperactivity disorder unstable dose methylphenidatecontaining product 30 day precede Visit 1 , dose adjustment anticipate study . 28 . Subject subject 's parent/legal guardian unwilling sign inform consent form . 29 . Subject concurrently participate another investigational study use investigational drug ( biologic ) device within 30 day prior Visit 1 . 30 . Subject plan anticipate travel outside allergenrich area one day RunIn phase ( Visit 1Visit 2 ) , two consecutive three total day Treatment Period ( Visit 2Visit 3 ) . ( Whenever possible , subject remain allergenrich area 3 day precede Visit 2 Visit 3 . ) 31 . Subject history presence cataract , ocular herpes , glaucoma . 32 . Subject history tuberculosis . 33 . Subject previously enrol study . 34 . Subject use Reference Product ( Nasonex ) within 3 month prior Visit 1 . 35 . History unresponsiveness Mometasone Nasal Spray . 36 . Members Investigational study staff , family member Investigational study staff .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>